SCHEMBL22765429

SCHEMBL22765429

CNC1CC2OC(C)(C1O)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 14/20 0.83
ROCK2 O75116 9/20 0.83
PRKCA P17252 7/20 0.83
MAP3K5 Q99683 3/20 0.83
PRKD3 O94806 7/20 0.81
PRKCG P05129 7/20 0.81
PRKCZ Q05513 7/20 0.81
PRKCB P05771 6/20 0.81
PRKCH P24723 6/20 0.81
PRKCI P41743 6/20 0.81
PRKCE Q02156 6/20 0.81
PRKCD Q05655 6/20 0.81
PRKD1 Q15139 6/20 0.81
EGFR P00533 5/20 0.81
PRKACA P17612 5/20 0.81
PRKACG P22612 4/20 0.81
PRKACB P22694 4/20 0.81
CHEK1 O14757 3/20 0.81
MAPK1 P28482 3/20 0.81
KDR P35968 3/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29884772 1.00 PRKCQ (0.83) PRKCQROCK2PRKCAMAP3K5PRKD3
SCHEMBL638600 1.00 PRKCQ (0.83) PRKCQROCK2PRKCAMAP3K5PRKD3
SCHEMBL260178 0.92 PRKCQ (0.81) PRKCQROCK2PRKCAMAP3K5PRKD3
SCHEMBL12253229 0.92 PRKCQ (0.81) PRKCQROCK2PRKCAMAP3K5PRKD3
SCHEMBL12253230 0.92 PRKCQ (0.81) PRKCQROCK2PRKCAMAP3K5PRKD3
SCHEMBL16437780 0.90 PRKCQ (0.76) PRKCQROCK2PRKCAMAP3K5PRKD3
SCHEMBL12570346 0.90 PRKCQ (1.00) PRKCQROCK2PRKCAMAP3K5PRKD3
SCHEMBL20841734 0.90 PRKCQ (1.00) PRKCQROCK2PRKCAMAP3K5PRKD3
SCHEMBL22765238 0.90 PRKCQ (1.00) PRKCQROCK2PRKCAMAP3K5PRKD3
SCHEMBL12570343 0.90 PRKCQ (1.00) PRKCQROCK2PRKCAMAP3K5PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002784-A1 COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS ORCHARD THERAPEUTICS (EUROPE) LIMITED (GB) 2023-01-05 US disclosed
WO-2020247814-A1 COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS ORCHARD THERAPEUTICS (EUROPE) LIMITED (GB) 2020-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002784-A1 COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS PHAX, CD4, POLM PRKCQ 2458/4885ROCK2 3751/4885PRKCA 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.